Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides
Button

Precious Metals
Battery Metals
Base Metals
Energy
Critical Minerals

cse:lxx

POPULAR ARTICLES

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

LATEST ARTICLES

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Latest News

Quarterly Cash Flow Report

Quarterly Activities Report

Micron Breaks Ground on Advanced Wafer Fabrication Facility in Singapore

Material revenue event from the Convera Commercial Agreement

Jura Announces Dismissal in Full of PEL's Appeal against certain reliefs granted in the Settlement Agreement Arbitral Award

Outlook Reports world

Precious Metals
- Gold
- Silver
Battery Metals
Energy
- Uranium
- Oil and Gas

Base Metals
Critical Metals
- Rare Earths
Industrial Metals
Agriculture

- Cleantech
- Emerging Tech

- Biotech
- Cannabis

- Psychedelics
- Pharmaceuticals

Featured Stocks

New Found Gold

New Found Gold (NFG:CC)

NFG:CC

Coelacanth Energy

Coelacanth Energy (CEI:CC)

CEI:CC

One Bullion: Advancing District-scale Gold Assets Across Botswana’s Greenstone Belts

OBUL:CC

Canada One Mining

Canada One Mining (CONE:CC)

CONE:CC

One Bullion Limited

One Bullion Limited (OBUL:CC)

OBUL:CC

ILC Critical Minerals

ILC Critical Minerals (ILC:CC)

ILC:CC

More featured stocks

Browse Companies

Precious Metals
Battery Metals
Energy

Base Metals
Critical Metals

MARKETS

COMMODITIES

CURRENCIES